Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06793189CT.gov MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL | — | Recruiting | — | — | — |
NCT06566807CT.gov Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT06513234CT.gov Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | — | Recruiting | — | — | — |
NCT06504940CT.gov Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) | — | Recruiting | — | — | — |
NCT06454968CT.gov Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. | — | Recruiting | — | — | — |
NCT05783596CT.gov Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05653271CT.gov ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT04796922CT.gov To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | — | Withdrawn | — | — | — |
NCT05846750CT.gov Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT05326308CT.gov Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | — | Recruiting | — | — | — |
Show 10 more trialsShow fewer
NCT05169658CT.gov Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT05100862CT.gov A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT04599634CT.gov Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | — | Completed | — | — | — |
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
NCT03322865CT.gov Obinutuzumab in Marginal Zone Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03276468CT.gov Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | — | Completed | — | — | — |
NCT03010358CT.gov Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02992522CT.gov Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01995669CT.gov Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marginal Zone Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | Ruijin Hospital | P3 | BB · 64 |
| Etoposide | University of Miami | P2 | BBB |
| Orelabrutinib | Henan Cancer Hospital | P4 | BBB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Vincristine Sulfate | Mayo Clinic | P2 | BBB |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Marginal Zone Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Marginal Zone Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-marginal-zone-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →